Article
Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in KRAS- and BRAF-mutant cancer cells.
Science signaling - 14 May 2024
Zhang Haibo, Read Abigail, Cataisson Christophe, Yang Howard H, Lee Wei-Chun, Turk Benjamin E, Yuspa Stuart H, Luo Ji
Abstract excerpt
The Ras-mitogen-activated protein kinase (MAPK) pathway is a major target for cancer treatment. To better understand the genetic pathways that modulate cancer cell sensitivity to MAPK pathway inhibitors, we performed a CRISPR knockout screen with MAPK pathway inhibitors on a colorectal cancer (CRC) cell line carrying mutant KRAS. Genetic deletion of the catalytic subunit of protein phosphatase 6 (PP6), encoded by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.